The development of therapeutics targeting MondoA and ChREBP is an active area of research, given their important roles in regulating glucose and lipid metabolism and their potential as targets for the treatment of diabetes, obesity, and metabolic diseases. This evidence concerns the gene MLXIP and Obesity.